Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.
|
16258005 |
2006 |
Malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
We investigated the association between genetic variation in the promoter region of MDM2 (c.-5+309G>T, rs2279744:g.G>T) and the coding region of TP53 (c.215G>C, rs1042522:g.G>C, designated Arg72Pro) and the risk of developing lung cancer.
|
16287156 |
2006 |
Carcinoma of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
We investigated the association between genetic variation in the promoter region of MDM2 (c.-5+309G>T, rs2279744:g.G>T) and the coding region of TP53 (c.215G>C, rs1042522:g.G>C, designated Arg72Pro) and the risk of developing lung cancer.
|
16287156 |
2006 |
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
We investigated the association between genetic variation in the promoter region of MDM2 (c.-5+309G>T, rs2279744:g.G>T) and the coding region of TP53 (c.215G>C, rs1042522:g.G>C, designated Arg72Pro) and the risk of developing lung cancer.
|
16287156 |
2006 |
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies.
|
17387621 |
2007 |
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, in this large collaborative study, we did not find an association of MDM2 SNP309 and TP53 R72P, separately or in interaction, with breast cancer.
|
17909070 |
2007 |
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, in this large collaborative study, we did not find an association of MDM2 SNP309 and TP53 R72P, separately or in interaction, with breast cancer.
|
17909070 |
2007 |
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies.
|
17387621 |
2007 |
Malignant Neoplasms
|
|
0.050 |
GeneticVariation
|
BEFREE |
Previous studies have suggested associations between variants in TP53 (R72P) and MDM2 (SNP309) and cancer risk.
|
17909070 |
2007 |
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
Previous studies have suggested associations between variants in TP53 (R72P) and MDM2 (SNP309) and cancer risk.
|
17909070 |
2007 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Polymorphisms of p53 Arg(72)Pro and p21 Ser(31)Arg did not show significant association with RCC.
|
17634539 |
2007 |
Renal Cell Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Polymorphisms of p53 Arg(72)Pro and p21 Ser(31)Arg did not show significant association with RCC.
|
17634539 |
2007 |
Gastric Cardia Adenocarcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
This study examined the effect of P53 Arg72Pro variants on transactivation of polymorphic MDM2 promoter (T309G) and their associations with risk of developing gastric cardia adenocarcinoma (GCA) in a Chinese population.
|
17638920 |
2007 |
Chronic Lymphocytic Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Although the p53 R72P SNPs and MDM2 SNP309 did not associate with any of the parameters studied, the BAX G125A SNPs was associated with a more advanced Binet stage at diagnosis, supporting a potential role for this variant in CLL disease progression.
|
17981213 |
2007 |
Giant Cell Arteritis
|
|
0.010 |
GeneticVariation
|
BEFREE |
This study examined the effect of P53 Arg72Pro variants on transactivation of polymorphic MDM2 promoter (T309G) and their associations with risk of developing gastric cardia adenocarcinoma (GCA) in a Chinese population.
|
17638920 |
2007 |
Gastric Cardia Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer.
|
17638920 |
2007 |
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Neither combined nor homozygous/heterozygous MDM-2 SNP309G was associated with total, premenopausal, or postmenopausal breast cancer risk; however, MDM-2 SNP309G, along with p53 Arg72Pro heterozygous variant, showed a significant protective association with premenopausal breast cancer risk (odds ratio [95% confidence interval]: 0.18 [0.02-1.20], p value; 0.041 for homozygous + heterozygous MDM-2 SNP309G).
|
17719241 |
2008 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Polymorphisms were identified within the TP53 (R72P and Ins16) and MDM2 (SNP309) genes that may further diminish TP53 tumor suppressor activity.
|
19046423 |
2008 |
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Neither combined nor homozygous/heterozygous MDM-2 SNP309G was associated with total, premenopausal, or postmenopausal breast cancer risk; however, MDM-2 SNP309G, along with p53 Arg72Pro heterozygous variant, showed a significant protective association with premenopausal breast cancer risk (odds ratio [95% confidence interval]: 0.18 [0.02-1.20], p value; 0.041 for homozygous + heterozygous MDM-2 SNP309G).
|
17719241 |
2008 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In addition, the TP53 R72P polymorphism and chromosome 1p/19q status, a major biomarker in oligodendroglial t</span>umors, were investigated.
|
18262501 |
2008 |
Liver carcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
Thus, MDM2 SNP 309 and p53 Arg72Pro are associated with the early development of HCC in Korean patients with chronic HBV infection.
|
18390844 |
2008 |
Malignant Neoplasms
|
|
0.050 |
GeneticVariation
|
BEFREE |
Recent studies have shown that functional polymorphisms at the MDM2 SNP309 T/G and p53 Arg72Pro may be associated with cancer susceptibility.
|
18575717 |
2008 |
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
Recent studies have shown that functional polymorphisms at the MDM2 SNP309 T/G and p53 Arg72Pro may be associated with cancer susceptibility.
|
18575717 |
2008 |
Non-Small Cell Lung Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
The purpose of the study was to investigate whether polymorphisms of p53 codon 72 (Arg72Pro) and MDM2 SNP309 (309T>G) affect p53 expression and the clinical outcome of patients with advanced nonsmall cell lung cancer (NSCLC).
|
18618574 |
2008 |
Treatment related acute myeloid leukaemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.
|
18426989 |
2008 |